Keyword: University of Pennsylvania
The partnership brings together J&J’s antibodies and a university’s AAVs in a bid to open up a new frontier in the fight against the disease.
The deal gives Arrakis rights to families of compounds that bind to three-way junctions found in folded RNA.
This past week saw new discoveries in treating heart failure, targeting Zika and dengue with one drug and inhibiting a cancer-promoting enzyme.
PARP inhibitor Lynparza may be able to kill cancer cells that don’t have BRCA mutations—provided it’s paired with a helper compound.
A multipronged immune attack that includes CAR-T treatments may be needed to fight glioblastoma, Penn scientists suggest.
This past week ushered in new discoveries in flu prevention, pancreatic cancer and HIV.
Penn scientists discovered three genetic variants that may help the immune system fight Alzheimer’s—and that may be targetable with drugs.
Novartis’ CAR-T cancer therapy has won the unanimous support of the FDA’s advisory committee, setting it up to win approval by October 3.
Sean Parker’s immuno-oncology institute has allied with Tessa Therapeutics to turn T-cell therapies against solid tumors.
Novartis has revealed the long-awaited interim Juliet data for its CAR-T candidate